Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies.

Maglione, Alessandro; Morra, Marta; Meroni, Raffaella; Matta, Manuela; Clerico, Marinella; Rolla, Simona

Maglione, Alessandro; Morra, Marta; Meroni, Raffaella; Matta, Manuela; Clerico, Marinella; Rolla, Simona.

Maglione A; Department of Clinical and Biological Sciences, University of Turin, Italy.
Morra M; Department of Clinical and Biological Sciences, University of Turin, Italy.
Meroni R; Department of Clinical and Biological Sciences, University of Turin, Italy.
Matta M; Department of Clinical and Biological Sciences, University of Turin, Italy.
Clerico M; Department of Clinical and Biological Sciences, University of Turin, Italy. Electronic address: marinella.clerico@unito.it.
Rolla S; Department of Clinical and Biological Sciences, University of Turin, Italy.

Mult Scler Relat Disord ; 61: 103776, 2022 May.

Article in English | MEDLINE | ID: covidwho-1757690

ABSTRACT

ABSTRACT

Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.

Subject(s)

COVID-19; Multiple Sclerosis; Antibodies, Viral; COVID-19/prevention & control; COVID-19 Vaccines; Humans; Immunoglobulin G/therapeutic use; Multiple Sclerosis/drug therapy; SARS-CoV-2

Keywords

Anti-SARS-Cov2 vaccine; Booster; Multiple sclerosis; Third dose

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Type of study: Experimental Studies Topics: Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2022.103776

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google